HRMY

Harmony Biosciences Holdings Inc

Feb 25 • 04:00PM ET

28.19

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Feb 24, 4:39 PMHarmony posts strong WAKIX growth, reiterates 2026 $1B+ guidance and pushes earliest generic entry to March 2030

Peers: MRK LLY PFE JNJ AMGN VRTX REGN GILD BIIB NBIX

| Held by: CALF JSMD USVM SFLO JSML FYX ECML RNIN SIXS VFMF

Scroll to Statements

Index	RUT	P/E	10.41	EPS (ttm)	2.71	Insider Own	13.08%	Shs Outstand	57.73M	Perf Week	-20.10%
Market Cap	1.62B	Forward P/E	6.62	EPS next Y	4.26	Insider Trans	-0.97%	Shs Float	50.06M	Perf Month	-24.54%
Enterprise Value	1.08B	PEG	0.31	EPS next Q	0.82	Inst Own	89.86%	Short Float	11.34%	Perf Quarter	-17.84%
Income	158.69M	P/S	1.87	EPS this Y	33.36%	Inst Trans	2.59%	Short Ratio	6.80	Perf Half Y	-24.67%
Sales	868.45M	P/B	1.87	EPS next Y	17.82%	ROA	13.98%	Short Interest	5.68M	Perf YTD	-24.67%
Book/sh	15.07	P/C	2.09	EPS next 5Y	21.03%	ROE	20.75%	52W High	40.87 -31.03%	Perf Year	-23.75%
Cash/sh	13.46	P/FCF	4.67	EPS past 3/5Y	-3.00% -	ROIC	15.58%	52W Low	25.52 10.46%	Perf 3Y	-37.81%
Dividend Est.	-	EV/EBITDA	4.63	Sales past 3/5Y	25.64% 40.30%	Gross Margin	74.42%	Volatility	10.75% 5.48%	Perf 5Y	-22.08%
Dividend TTM	-	EV/Sales	1.25	EPS Y/Y TTM	8.01%	Oper. Margin	24.00%	ATR (14)	1.98	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.58	Sales Y/Y TTM	21.51%	Profit Margin	18.27%	RSI (14)	26.87	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.60	EPS Q/Q	-54.92%	SMA20	-19.34%	Beta	0.88	Target Price	42.82
Payout	0.00%	Debt/Eq	0.27	Sales Q/Q	21.12%	SMA50	-22.85%	Rel Volume	1.73	Prev Close	28.19
Employees	293	LT Debt/Eq	0.17	Earnings	Feb 24 BMO	SMA200	-17.38%	Avg Volume	834.19K	Price	28.19
IPO	Aug 19, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-56.61% 1.44%	Trades		Volume	1,443,386	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-26	Downgrade	Truist	Buy → Hold
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-11-26	Resumed	UBS	Neutral	$46
Jul-21-25	Initiated	Truist	Buy	$48
Jul-10-25	Resumed	Goldman	Neutral	$33
Jun-02-25	Resumed	Oppenheimer	Outperform	$61
Feb-11-25	Initiated	Deutsche Bank	Buy	$55
Dec-17-24	Initiated	H.C. Wainwright	Buy	$75
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy	$56
Jun-21-24	Initiated	Citigroup	Buy	$48
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform	$30
Sep-25-23	Downgrade	Goldman	Neutral → Sell	$40 → $31
Sep-07-23	Initiated	Berenberg	Buy	$59
Apr-20-23	Initiated	BofA Securities	Neutral	$35
Oct-14-22	Upgrade	Jefferies	Hold → Buy	$57 → $61
Oct-14-22	Upgrade	Janney	Neutral → Buy	$57 → $61
Aug-03-22	Downgrade	Jefferies	Buy → Hold	$57
Jul-13-22	Downgrade	Goldman	Buy → Neutral	$55
Jul-07-22	Initiated	Mizuho	Buy	$64

Show Previous Ratings

Today 11:03AM	BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
10:21AM	RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up (Zacks)
09:12AM	Corcept's Q4 Earnings and Revenues Fall Short of Estimates (Zacks)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
08:55AM	Loading…
08:55AM	Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y (Zacks)
Feb-24-26 08:05PM	Harmony Biosciences Holdings, Inc. Q4 2025 Earnings Call Summary (Moby)
04:02PM	Harmony Biosciences Holdings Inc (HRMY) Q4 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
12:08PM	AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
11:47AM	Harmony Biosciences Q4 Earnings Call Highlights (MarketBeat)
11:35AM	BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market (Zacks)
09:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion (Business Wire)
Feb-23-26 11:12AM	Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks) -7.85%
10:47AM	FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug (Zacks)
07:23AM	Loading…
07:23AM	Harmony Biosciences Holdings Inc (HRMY) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-20-26 10:20AM	Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View (Zacks) -15.21%
09:59AM	Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down (Zacks)
Feb-19-26 11:59AM	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth (Zacks)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
04:07AM	Zacks.com featured highlights include Harmony Biosciences, Tripadvisor, The AES and Concentrix (Zacks)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
10:45AM	4 Value Stocks to Buy Now Amid AI-Driven Market Volatility (Zacks)
09:41AM	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients (Zacks)
09:32AM	Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo (Zacks)
07:14AM	Top 5 Bargain P/B Stocks Investors Should Watch Now (Zacks)
Feb-17-26 10:00AM	Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Expected to Decline (Zacks)
08:05AM	Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy (Business Wire)
Feb-16-26 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Harmony Biosciences (HRMY) (Zacks)
09:55AM	Loading…
Feb-12-26 09:55AM	Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Here's is How to Trade (Zacks)
Feb-11-26 11:40AM	HRMY vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? (Zacks)
Feb-10-26 08:05AM	Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (Business Wire)
Feb-05-26 12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
10:22AM	Zacks.com featured highlights include Harmony Biosciences, Adecoagro, Sociedad Quimica y Minera de Chile, Angi and PHINIA (Zacks)
Feb-04-26 09:39AM	5 Value Picks Amid AI-Driven Tech Sell-Off & U.S.-Iran Tensions (Zacks)
Feb-02-26 07:20AM	5 Low Price-to-Book Stocks That Are Worth Watching in February (Zacks)
06:14AM	Zacks.com featured highlights include Harmony Biosciences, Universal Health Services, Concentrix and Global Payments (Zacks)
Jan-30-26 11:30AM	4 Value Stocks to Consider as Tech Volatility Weighs on Wall Street (Zacks)
Jan-29-26 03:00PM	4 GARP Stocks With Attractive PEG Ratios and Strong Growth Outlooks (Zacks)
12:45PM	Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Jan-28-26 12:24PM	How Harmony Biosciences Can Prove Its Skeptics Wrong (Motley Fool)
12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
Jan-27-26 12:22PM	Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? (Motley Fool)
Jan-26-26 12:21PM	I Was Shocked to Find This Value-Priced Biotech Growth Stock (Motley Fool)
11:40AM	HRMY or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
09:40AM	Should Value Investors Buy Harmony Biosciences (HRMY) Stock? (Zacks)
Jan-15-26 08:47AM	Buy These 5 Price-to-Book Value Stocks for Gains in 2026 (Zacks)
Jan-13-26 12:45PM	Harmony Biosciences (HRMY) is an Incredible Growth Stock: 3 Reasons Why (Zacks) -6.56%
Jan-12-26 08:05AM	Harmony Biosciences Guides to Over $1 Billion in WAKIX Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation (Business Wire)
Jan-08-26 11:40AM	HRMY vs. LQDA: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? (Zacks)
Jan-07-26 08:05AM	Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-08-25 08:05AM	Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome (Business Wire)
Dec-02-25 08:05AM	Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
Nov-24-25 08:05AM	Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation (Business Wire)
Nov-19-25 08:05AM	Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence (Business Wire)
Nov-18-25 08:05AM	Harmony Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Nov-05-25 08:01AM	Harmony Biosciences Holdings Inc (HRMY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Nov-04-25 08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M (Business Wire)
Nov-03-25 07:38AM	Earnings To Watch: Harmony Biosciences Holdings Inc (HRMY) Reports Q3 2025 Result (GuruFocus.com)
Oct-31-25 10:29PM	Truist Financial Reiterates a Buy on Harmony Biosciences (HRMY) (Insider Monkey)
Oct-29-25 10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 10:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-24-25 04:38AM	Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last? (Zacks)
Oct-23-25 08:05AM	Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance (Business Wire) +12.68%
Oct-09-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Sep-29-25 06:54PM	H.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 Setback (Insider Monkey)
Sep-25-25 09:59AM	HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal (Zacks)
Sep-24-25 01:20PM	Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study (Benzinga) -16.56%
01:02PM	Harmony Biosciences Whiffs In 'Undruggable' Genetic Disease; Shares Tumble (Investor's Business Daily)
08:00AM	Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome (Business Wire)
Sep-17-25 02:27PM	UBS Maintains a Buy Rating on Harmony Biosciences Holdings (HRMY), Sets a $50 PT (Insider Monkey)
Sep-15-25 02:18PM	11 fast-growing small-cap stocks that could get a boost from the Fed's next move (MarketWatch)
Aug-29-25 05:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Expands WAKIX With FDA Nod for Prader-Willi (Insider Monkey)
Aug-26-25 08:05AM	Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress (Business Wire)
Aug-21-25 08:05AM	Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference (Business Wire)
Aug-12-25 09:11AM	H.C. Wainwright Remains a Buy on Harmony Biosciences Holdings (HRMY) (Insider Monkey)
Aug-08-25 10:15AM	Can Cannabis Stocks Reverse Their Prolonged Downtrend? (Zacks)
Aug-05-25 08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates (Zacks)
07:30AM	Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 (Business Wire)
Aug-04-25 04:35PM	Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory (Insider Monkey)
09:36AM	Harmony Biosciences Holdings Inc (HRMY) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Jul-30-25 10:00AM	Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-29-25 10:00AM	Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-25-25 09:58AM	REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth? (Zacks)
Jul-23-25 11:04AM	Harmony Biosciences Advances Pipeline While Navigating Analyst Caution (Insider Monkey)
Jul-22-25 01:30PM	Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View (Zacks)
08:53AM	5 High Earnings Yield Stocks to Tap Into Value Investing Gains (Zacks)
08:05AM	Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 (Business Wire)
Jul-17-25 12:10PM	Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again (Zacks)
Jul-15-25 12:45PM	3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY) (Zacks)
11:40AM	HRMY vs. ILMN: Which Stock Should Value Investors Buy Now? (Zacks)
09:55AM	Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect? (Zacks)
09:40AM	Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? (Zacks)
08:05AM	Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series (Business Wire)
Jul-14-25 11:30AM	Mizuho Reaffirms "Outperform" on Harmony Biosciences (HRMY) for BP1.15205 Data (Insider Monkey)
Jul-10-25 11:41AM	Harmony Biosciences Preclinical Data for Narcolepsy Drug BP1.15205 Shows Promise (Insider Monkey)

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	37.15	3,746	139,171	24,521	Jan 28 08:19 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 25 '26	Option Exercise	0.00	4,725	0	4,725	Jan 26 04:49 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 24 '26	Option Exercise	0.00	3,813	0	3,813	Jan 26 04:49 PM
Serafin Andrew	CHIEF STRATEGY OFFICER	Jan 25 '26	Option Exercise	0.00	2,600	0	2,600	Jan 26 04:48 PM
Serafin Andrew	CHIEF STRATEGY OFFICER	Jan 24 '26	Option Exercise	0.00	2,500	0	2,500	Jan 26 04:48 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Jan 25 '26	Option Exercise	0.00	2,662	0	2,662	Jan 26 04:45 PM
Budur Kumar	CHIEF MEDICAL OFFICER	Jan 24 '26	Option Exercise	0.00	2,188	0	2,188	Jan 26 04:45 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Jan 25 '26	Option Exercise	0.00	13,000	0	13,000	Jan 26 04:43 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Jan 24 '26	Option Exercise	0.00	10,500	0	10,500	Jan 26 04:43 PM
SANDIP KAPADIA	Officer	Jan 26 '26	Proposed Sale	36.82	3,746	137,928		Jan 26 04:30 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 15 '26	Sale	35.92	20,961	752,833	0	Jan 20 08:39 PM
SANDIP KAPADIA	Officer	Jan 15 '26	Proposed Sale	36.04	20,961	755,434		Jan 15 04:22 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Dec 12 '25	Option Exercise	8.22	20,000	164,400	20,000	Dec 17 05:25 PM
Dayno Jeffrey M.	PRESIDENT, CEO	Dec 12 '25	Sale	40.11	25,933	1,040,103	0	Dec 17 05:25 PM
JEFFREY M DAYNO	Director	Dec 12 '25	Proposed Sale	39.59	25,933	1,026,687		Dec 12 04:25 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Dec 05 '25	Option Exercise	29.03	20,000	580,600	20,000	Dec 09 04:10 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Dec 05 '25	Sale	39.54	20,000	790,896	0	Dec 09 04:10 PM
SANDIP KAPADIA	Officer	Dec 05 '25	Proposed Sale	38.25	20,000	765,000		Dec 05 04:30 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Nov 21 '25	Sale	35.00	3,427	119,945	0	Nov 25 04:10 PM
SANDIP KAPADIA	Officer	Nov 21 '25	Proposed Sale	33.39	3,427	114,428		Nov 21 04:46 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Sep 30 '25	Option Exercise	0.00	45,000	0	45,000	Oct 02 04:05 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Aug 15 '25	Sale	36.50	21,573	787,378	0	Aug 19 04:15 PM
SANDIP KAPADIA	Officer	Aug 15 '25	Proposed Sale	36.51	21,573	787,630		Aug 15 04:28 PM
JEFFREY G DIERKS	Former Officer	Jun 10 '25	Proposed Sale	35.98	5,615	202,009		Jun 10 04:29 PM
JEFFREY G DIERKS	Former Officer	May 19 '25	Proposed Sale	35.56	9,844	350,083		May 19 04:06 PM
JEFFREY G DIERKS	Former Officer	May 16 '25	Proposed Sale	35.09	2,292	80,427		May 16 04:21 PM
JEFFREY G DIERKS	Former Officer	May 12 '25	Proposed Sale	35.19	5,000	175,955		May 12 04:18 PM
Budur Kumar	CHIEF MEDICAL OFFICER	May 01 '25	Option Exercise	0.00	18,750	0	18,750	May 09 04:07 PM
JEFFREY G DIERKS	Former Officer	May 09 '25	Proposed Sale	34.22	4,972	170,119		May 09 04:07 PM
JEFFREY G DIERKS	Former Officer	May 08 '25	Proposed Sale	33.76	13,000	438,873		May 08 04:15 PM
JEFFREY G DIERKS	Former Officer	May 07 '25	Proposed Sale	32.47	31,000	1,006,645		May 07 04:13 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Apr 01 '25	Sale	32.54	6,987	227,386	0	Apr 03 04:15 PM
SANDIP KAPADIA	Officer	Apr 01 '25	Proposed Sale	33.19	6,986	231,865		Apr 01 04:27 PM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Mar 29 '25	Option Exercise	0.00	15,000	0	15,000	Apr 01 04:10 PM
Dierks Jeffrey	CHIEF COMMERCIAL OFFICER	Mar 03 '25	Option Exercise	8.22	4,869	40,023	4,869	Mar 05 04:05 PM
Dierks Jeffrey	CHIEF COMMERCIAL OFFICER	Mar 03 '25	Sale	32.67	4,869	159,090	0	Mar 05 04:05 PM
JEFFREY G DIERKS	Officer	Mar 03 '25	Proposed Sale	33.85	4,869	164,816		Mar 03 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HRMY

Harmony Biosciences Holdings Inc

Upgrade your FINVIZ experience